公开(公告)号：EP2424564B1

公开(公告)日：2015-02-25

申请号：EP10715245.6

申请日：2010-04-26

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  INSTITUT PASTEUR DE LILLE ,  National University of Ireland, Maynooth

发明人： LOCHT, Camille ,  MAHON, Bernard ,  KAVANAGH, Heather

IPC分类号： A61K39/10

CPC分类号： A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  A61K2039/544

摘要： The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

公开(公告)号：EP2424564A1

公开(公告)日：2012-03-07

申请号：EP10715245.6

申请日：2010-04-26

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  INSTITUT PASTEUR DE LILLE ,  National University of Ireland, Maynooth

发明人： LOCHT, Camille ,  MAHON, Bernard ,  KAVANAGH, Heather

IPC分类号： A61K39/10

CPC分类号： A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  A61K2039/544

摘要： The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

公开(公告)号：EP3800244A1

公开(公告)日：2021-04-07

申请号：EP20183971.9

申请日：2007-03-07

申请人： Institut Pasteur de Lille ,  INSERM - Institut National de la Santé et de la Recherche Médicale

发明人： LOCHT, Camille ,  MIELCAREK, Nathalie ,  DEBRIE, Anne-Sophie ,  RAZE, Dominique ,  BERTOUT, Julie

IPC分类号： C12N1/36 ,  A61K39/10 ,  A61K39/02 ,  A61K39/00 ,  A61P11/00 ,  A61P31/04

摘要： A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

公开(公告)号：EP3459966A1

公开(公告)日：2019-03-27

申请号：EP18194351.5

申请日：2013-10-17

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Institut Pasteur De Lille ,  Université de Lille

发明人： LOCHT, Camille ,  MIELCAREK, Nathalie ,  KAMMOUN, Hana

IPC分类号： C07K14/235 ,  C12N1/36

摘要： The present invention relates to a genetically attenuated Bordetella pertussis strain comprising a mutated pertussis toxin ( ptx ) gene, and a heterologous ampG gene and expressing a hybrid protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitode or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated.
The invention further provides a live attenuated vaccine for the treatment of a mucosal or systemic infectious disease comprising a Bordetella pertussis strain as defined above intended to elicit a immune response against pathogens responsible for systemic or mucosal infections, including of the upper or lower respiratory tract.
The present invention also relates to a method for prophylaxis of an infectious disease in a mammal, comprising administering to said mammal an effective amount of a vaccine comprising in a suitable vehicle a genetically attenuated Bordetella pertussis strain comprising a mutated pertussis toxin ( ptx ) gene, and a heterologous ampG gene and expressing a hybrid protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated.
The invention provides a method for enhancing the immune response toward a pathogen, in a mammal, comprising administering a vaccine based on a Bordetella recombinant vector, wherein said Bordetella expresses a fusion protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment of said pathogen against which the immune response is sought and wherein in said recombinant strain, the gene coding for the native FHA protein is inactivated.

公开(公告)号：EP2909229B1

公开(公告)日：2018-12-12

申请号：EP13777082.2

申请日：2013-10-17

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  INSTITUT PASTEUR DE LILLE ,  Université de Lille

发明人： LOCHT, Camille ,  MIELCAREK, Nathalie ,  KAMMOUN, Hana

IPC分类号： C07K14/235 ,  C12N1/36 ,  A61K39/02 ,  A61K39/12 ,  A61K39/00 ,  A61K39/09

CPC分类号： C12N1/36 ,  A61K39/092 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  C07K14/235 ,  C12N2760/16134 ,  C12N2760/18534

摘要： The present invention relates to a recombinant genetically attenuated Bordetella strain expressing a hybrid protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated. The Bordetella strain is preferably a Bordetella pertussis strain, but may also be another Bordetella species, such as Bordetella bronchiseptica, Bordetella parapertussis or Bordetella avium. The invention further provides a life attenuated vaccine for the treatment of a mucosal or systemic infectious disease comprising a Bordetella strain as defined above intended to elicit a immune response against pathogens responsible for systemic or mucosal infections, including of the upper or lower respiratory tract. The present invention also relates to a method for prophylaxis of an infectious disease in a mammal, comprising administering to said mammal an effective amount of a vaccine comprising in a suitable vehicle a recombinant attenuated Bordetella strain expressing a fusion protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitome or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated.

公开(公告)号：EP2909229A1

公开(公告)日：2015-08-26

申请号：EP13777082.2

申请日：2013-10-17

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  INSTITUT PASTEUR DE LILLE ,  Université de Droit et de Santé de Lille II

发明人： LOCHT, Camille ,  MIELCAREK, Nathalie ,  KAMMOUN, Hana

IPC分类号： C07K14/235 ,  C12N1/36

CPC分类号： C12N1/36 ,  A61K39/092 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  C07K14/235 ,  C12N2760/16134 ,  C12N2760/18534

摘要： The present invention relates to a recombinant genetically attenuated Bordetella strain expressing a hybrid protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated. The Bordetella strain is preferably a Bordetella pertussis strain, but may also be another Bordetella species, such as Bordetella bronchiseptica, Bordetella parapertussis or Bordetella avium. The invention further provides a life attenuated vaccine for the treatment of a mucosal or systemic infectious disease comprising a Bordetella strain as defined above intended to elicit a immune response against pathogens responsible for systemic or mucosal infections, including of the upper or lower respiratory tract. The present invention also relates to a method for prophylaxis of an infectious disease in a mammal, comprising administering to said mammal an effective amount of a vaccine comprising in a suitable vehicle a recombinant attenuated Bordetella strain expressing a fusion protein comprising the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitome or antigenic protein or protein fragment, different from FHA, wherein the gene coding for the native FHA protein is inactivated.

公开(公告)号：EP1763574A2

公开(公告)日：2007-03-21

申请号：EP05762329.0

申请日：2005-06-30

申请人： INSTITUT PASTEUR DE LILLE ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  UNIVERSITE LIBRE DE BRUXELLES ,  UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2

发明人： LOCHT, Camille ,  MASCART, Françoise ,  TEMMERMAN, Stéphane ,  HOUGARDY, Jean-Michel ,  PLACE, Sammy ,  SERGHERAERT, Christian

IPC分类号： C12G1/02

CPC分类号： G01N33/5695

摘要： The present invention concerns methods for in vitro detection of an infection by Mycobacterium tuberculosis in mammals, and methods for in vitro distinction between mammals infected with Mycobacterium tuberculosis in which the disease is declared (active form) and mammals which are infected but asymptomatic for tuberculosis (latent form), and a method for in vitro distinction between mammals presenting an active form of tuberculosis and mammals not infected by M tuberculosis or presenting a latent form of tuberculosis. The present invention also pertains to kits for detection and distinction between infected mammals presenting tuberculosis symptoms and infected mammals with no disease development, and a kit for distinguishing between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis.

公开(公告)号：EP3459966B1

公开(公告)日：2019-11-27

申请号：EP18194351.5

申请日：2013-10-17

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Institut Pasteur De Lille ,  Université de Lille

发明人： LOCHT, Camille ,  MIELCAREK, Nathalie ,  KAMMOUN, Hana

IPC分类号： A61K39/02 ,  A61K39/09 ,  A61K39/12 ,  C07K14/235 ,  C12N1/36 ,  A61K39/00

公开(公告)号：EP2838990A1

公开(公告)日：2015-02-25

申请号：EP12874533.8

申请日：2012-04-16

申请人： Aeras Global TB Vaccine Foundation ,  INSERM - Institut National de la Santé et de la Recherche Médicale

发明人： FULKERSON, John ,  BRENNAN, Michael ,  VELMURUGAN, Kamalakannan ,  LOCHT, Camille

IPC分类号： C12N1/21 ,  C12N15/62 ,  C07K19/00 ,  C12P21/00

CPC分类号： C07K14/35 ,  A61K39/04 ,  A61K49/0006 ,  A61K2039/523 ,  A61K2039/53 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/40 ,  C07K2319/90

摘要： Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.

公开(公告)号：EP1292333B1

公开(公告)日：2007-02-07

申请号：EP01945376.0

申请日：2001-06-07

申请人： INSTITUT PASTEUR DE LILLE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： CAPRON, André ,  LOCHT, Camille ,  MENOZZI, Franco ,  POULAIN-GODEFROY, Odile ,  RIVEAU, Gilles

IPC分类号： A61K39/39 ,  A61P31/04 ,  A61P33/00 ,  A61P37/04

CPC分类号： C07K14/235 ,  A61K39/099 ,  A61K39/39 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55511 ,  A61K2039/55516 ,  Y02A50/412 ,  Y02A50/423

摘要： The invention concerns the use of the FHA protein or part of the FHA protein, in free form, as adjuvant of the immune response or as immunostimulant in a human or an animal. The invention also concerns adjuvant and immunostimulatory compositions comprising FHA protein or a fragment thereof, and the use of said compositions for making vaccines.